BPC-157

The internet's favorite 'healing peptide.' The rodent literature is large and often positive for gut, tendon, and muscle injury models. Quality human RCTs are essentially absent, and US compounding policy has moved against it.

A 15-residue fragment derived from a gastric protein. Proposed actions include angiogenic signaling (VEGFR2), nitric-oxide modulation, and effects on growth-factor pathways. Human target engagement is not established.

Dozens of animal studies report faster tendon/ligament healing and GI mucosal protection. Human evidence is anecdotal plus a few poorly controlled or unpublished reports. That gap is the entire story: mechanism hypotheses outrun clinical proof.

Not FDA-approved. In 2023 the FDA placed BPC-157 in Category 2 under compounding policy (safety/characterization concerns), restricting 503A/503B compounding. Sold online as a research chemical.

Not an FDA-approved drug. In 2023 FDA placed BPC-157 in Category 2 (significant compounding safety concerns). Nominators later withdrew that Category 2 placement; in July 2026 FDA's Pharmacy Compounding Advisory Committee narrowly recommended adding BPC-157 to the 503A bulks list for ulcerative colitis. A PCAC vote is not a listing, not an approval, and not a pharmacy green light. Until FDA actually places it on the bulks list, compounding is not a generally authorized US pathway. Research-chemical vendors remain the unofficial channel.

Same four pathways as the Sourcing guide.

No. Insurers do not pay for unapproved research peptides. A clinic cash protocol is not a covered benefit.

One of the most widely sold 'healing peptides' online, usually as a lyophilized vial labeled not for human use. Independent testing in adjacent research-chemical markets has found wrong identity, under-dosing, and contamination. There is no lot-level regulator behind those vials.

Strand does not list vendors. See the grey market.

Unknown long-term human safety. Theoretical concerns include unregulated angiogenesis in occult malignancy. Product identity and sterility in research vials are not guaranteed. Do not treat animal milligram-per-kilogram figures as a human protocol.

• No adequate human RCTs; animal milligram-per-kilogram figures are not a human protocol.
• Theoretical angiogenesis concern in occult malignancy.
• Immunogenicity and characterization problems were why FDA staff opposed compounding.
• Sterility failure of a multi-use vial is an infection pathway.
• A PCAC recommendation is not permission to inject a research chemical.

• Preclinical tendon review · 2019 · Cell Tissue Res

  Gwyer, Wragg, Wilson. Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing. PMID 30915550.

• FDA compounding risks

  Category 2 / withdrawn-nomination safety notes on BPC-157 (immunogenicity, characterization).

• PCAC July 2026

  Advisory committee discussed 503A bulks listing for ulcerative colitis — recommendation is not a listing.